Effects of BCR-ABL inhibitors on anti-tumor immunity

Current Medicinal Chemistry

Volumn 18, Issue 34, 2011, Pages 5174-5184

  Krusch, M ^a   Salih, H R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

BCR ABL inhibitors; CML; Dasatinib; Imatinib; Immune surveillance; Nilotinib

Indexed keywords

DASATINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NILOTINIB; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; TUMOR ANTIGEN;

CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; NATURAL KILLER CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; FUSION PROTEINS, BCR-ABL; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; T-LYMPHOCYTES; THIAZOLES;

EID: 82255169327     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798184271     Document Type: Review

References (107)

1. Druker, B. J. Translation of the Philadelphia chromosome into therapy for CML. Blood, 2008, 112, 4808-4817.
2. Lee, S. J. Chronic myelogenous leukaemia. Br. J. Haematol. 2000, 111, 993-1009. (Pubitemid 32104911)
3. Kiladjian, J. J.; Mesa, R. A.; Hoffman, R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood, 2011, 117, 4706-4715.
4. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100-104.
5. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344, 1031-1037. (Pubitemid 32267972)
6. Cohen, M H.; Williams, G.; Johnson, J. R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J., Kim, S. K.; Wood, R.; Rothmann, M.; Chen, G.; U, K. M.; Staten, A. M.; Pazdur. R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res, 2002, 8, 935-942. (Pubitemid 34520420)
7. Hughes, T. P.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M. L.; Gathmann, I.; Bolton, A. E.; van Hoomissen, I. C.; Goldman, J. M.; Radich, J. P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 2003, 349, 1423-1432. (Pubitemid 37211057)
8. Hochhaus, A., O'Brien, S. G.; Guilhot, F.; Druker, B. J.; Branford, S.; Foroni, L.; Goldman, J. M.; Muller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23, 1054-1061.
9. Cortes, J.; Talpaz, M.; O'Brien, S.; Jones, D.; Luthra, R.; Shan, J.; Giles, F.; Faderl, S.; Verstovsek, S.; Garcia-Manero, G.; Rios, M. B.; Kantarjian, H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res., 2005, 11, 3425-3432. (Pubitemid 40627896)
10. Weisberg, E. P.; Manley, W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141. (Pubitemid 40248339)
11. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305, 399-401. (Pubitemid 38938156)
12. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J. D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann, O. G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., 2006, 354, 2542-2551. (Pubitemid 43882350)
13. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354, 2531-2541. (Pubitemid 43882349)
14. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; and Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res., 2005, 65, 4500-4505. (Pubitemid 40740783)
15. Weisberg, E.; Manley, P. W.; Cowan-Jacob, S. W.; Hochhaus, A.; Griffin, J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nat. Rev. Cancer, 2007, 7, 345-356. (Pubitemid 46652483)
16. Kantarjian, H. M.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Moiraghi, B.; Shen, Z.; Mayer, J.; Pasquini, R.; Nakamae, H.; Huguet, F.; Boque, C.; Chuah, C.; Bleickardt, E.; Bradley-Garelik, M. B.; Zhu, C.; Szatrowski, T.; Shapiro, D.; Baccarani, M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 2010, 362, 2260-2270.
17. Saglio, G.; Kim, D. W.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R. E.; Hochhaus, A.; Hughes, T. P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A.; Larson, R. A.; Kantarjian, H. M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 2010, 362, 2251-2259.
18. Mahon, F. X.; Rea, D.; Guilhot, J.; Guilhot, F.; Huguet, F.; Nicolini, F.; Legros, L.; Charbonnier, A.; Guerci, A.; Varet, B.; Etienne, G.; Reiffers, J.; Rousselot, P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol., 2010, 11, 1029-1035.
19. Redner, R. L. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist., 2010, 15, 182-186.
20. Ross, D. M.; Hughes, T. P.; Melo, J. V. Do we have to kill the last CML cell? Leukemia, 2011, 25, 193-200.
21. Holyoake, T.; Jiang, X.; Eaves, C.; Eaves, A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood, 1999, 94, 2056-2064. (Pubitemid 29430422)
22. Dorsey, J. F.; Cunnick, J. M.; Lanehart, R.; Huang, M.; Kraker, A. J.; Bhalla, K. N.; Jove, R.; Wu, J. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia, 2002, 16, 1589-1595.
23. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 2006, 107, 4532-4539. (Pubitemid 43801382)
24. Jiang, X.; Zhao, Y.; Smith, C.; Gasparetto, M.; Turhan, A.; Eaves, A.; Eaves, C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia, 2007, 21, 926-935. (Pubitemid 46672068)
25. Corbin, A. S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M. W.; Druker, B. J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest, 2011, 121, 396-409.
26. Horowitz, M. M.; Gale, R. P.; Sondel, P. M.; Goldman, J. M.; Kersey, J.; Kolb, H. J.; Rimm, A. A.; Ringden, O.; Rozman, C.; Speck, B.; Truitt, R. L.; Zwaan, F. E.; Bortin, M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990, 75, 555-562. (Pubitemid 20069191)
27. Kolb, H. J.; Schattenberg, A.; Goldman, J. M.; Hertenstein, B.; Jacobsen, N.; Arcese, W.; Ljungman, P.; Ferrant, A.; Verdonck, L.; Niederwieser, D.; van Rhee, F.; Mittermueller, J.; de Witte, T.; Holler, E.; and Ansari, H. Graftversus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 1995, 86, 2041-2050.
28. Mackinnon, S.; Papadopoulos, E. B.; Carabasi, M. H.; Reich, L.; Collins, N. H.; Boulad, F.; Castro-Malaspina, H.; Childs, B. H.; Gillio, A. P.; Kernan, N. A.; Small, T. N.; Young, J. W.; O'Reilly, R. J. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graftversus-leukemia responses from graft-versus-host disease. Blood, 1995, 86, 1261-1268.
29. Mahon, F. X.; Delbrel, X.; Cony-Makhoul, P.; Faberes, C.; Boiron, J. M.; Barthe, C.; Bilhou-Nabera, C.; Pigneux, A.; Marit, G.; Reiffers, J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J. Clin. Oncol., 2002, 20, 214-220. (Pubitemid 34032614)
30. Verbeek, W.; Konig, H.; Boehm, J.; Kohl, D.; Lange, C.; Heuer, T.; Scheibenbogen, C.; Reis, H. E.; Hochhaus, A.; Graeven, U. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Acta Haematol., 2006, 115, 109-112. (Pubitemid 43130443)
31. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
32. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Andre, F.; Tesniere, A.; Kroemer, G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest, 2008, 118, 1991-2001. (Pubitemid 351872317)
33. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity., 2004, 21, 137-148. (Pubitemid 39094044)
34. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 2006, 6, 715-727. (Pubitemid 44453458)
35. Finn, O. J. Cancer immunology. N. Engl. J. Med., 2008, 358, 2704-2715.
36. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol., 2007, 25, 1035-1044. (Pubitemid 47517638)
37. Rix, U.; Hantschel, O.; Durnberger, G.; Remsing Rix, L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Kocher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063. (Pubitemid 350248462)
38. Hantschel, O.; Rix, U.; Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma, 2008, 49, 615-619. (Pubitemid 351517198)
39. Lanzavecchia, A.; Sallusto, F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science, 2000, 290, 92-97.
40. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y. J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annu. Rev. Immunol., 2000, 18, 767-811. (Pubitemid 30365397)
41. Driessens, G.; Kline, J.; Gajewski, T. F. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev., 2009, 229, 126-144.
42. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol., 2006, 6, 295-307.
43. Steinman, R. M.; Banchereau, J. Taking dendritic cells into medicine. Nature, 2007, 449, 419-426. (Pubitemid 47509552)
44. Melief, C. J. Cancer immunotherapy by dendritic cells. Immunity., 2008, 29, 372-383.
45. Appel, S.; Balabanov, S.; Brummendorf, T. H.; Brossart, P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells, 2005, 23, 1082-1088. (Pubitemid 41377724)
46. Wolf, D.; Tilg, H.; Rumpold, H.; Gastl, G.; Wolf, A. M. The kinase inhibitor imatinib-an immunosuppressive drug? Curr. Cancer Drug Ta rgets., 2007, 7, 251-258. (Pubitemid 46699076)
47. Seggewiss, R.; Price, D. A.; Purbhoo, M. A. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy., 2008, 10, 633-641.
48. Appel, S.; Boehmler, A. M.; Grunebach, F.; Muller, M. R.; Rupf, A.; Weck, M. M.; Hartmann, U.; Reichardt, V. L.; Kanz, L.; Brummendorf, T. H.; Brossart, P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood, 2004, 103, 538-544. (Pubitemid 38140084)
49. Appel, S.; Rupf, A.; Weck, M. M.; Schoor, O.; Brummendorf, T. H.; Weinschenk, T.; Grunebach, F.; Brossart, P. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin. Cancer Res., 2005, 11, 1928-1940. (Pubitemid 40471859)
50. Taieb, J.; Maruyama, K.; Borg, C.; Terme, M.; Zitvogel, L. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood, 2004, 103, 1966-1967. (Pubitemid 38269001)
51. Wang, H.; Cheng, F.; Cuenca, A.; Horna, P.; Zheng, Z.; Bhalla, K.; Sotomayor, E. M. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood, 2005, 105, 1135-1143. (Pubitemid 40170886)
52. Sato, N.; Narita, M.; Takahashi, M.; Yagisawa, K.; Liu, A.; Abe, T.; Nikkuni, K.; Furukawa, T.; Toba, K.; Aizawa, Y. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol. Oncol., 2003, 21, 67-75. (Pubitemid 36717431)
53. Mohty, M.; Jourdan, E.; Mami, N. B.; Vey, N.; Damaj, G.; Blaise, D.; Isnardon, D.; Olive, D.; Gaugler, B. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood, 2004, 103, 4666-4668. (Pubitemid 38746000)
54. Rohon, P.; Porkka, K.; Mustjoki, S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur. J. Haematol., 2010, 85, 387-398.
55. Hus, I.; Tabarkiewicz, J.; Lewandowska, M.; Wasiak, M.; Wdowiak, P.; Kusz, M.; Legiec, M.; Dmoszynska, A.; Rolinski, J. Evaluation of monocytederived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia Histochem. Cytobiol., 2011, 49:153-160.
56. Boissel, N.; Rousselot, P.; Raffoux, E.; Cayuela, J. M.; Soulier, J.; Mooney, N.; Charron, D.; Dombret, H.; Toubert, A.; Rea, D. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukoc. Biol., 2006, 79, 747-756. (Pubitemid 44835607)
57. Dietz, A. B.; Souan, L.; Knutson, G. J.; Bulur, P. A., Litzow, M. R.; Vuk-Pavlovic, S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood, 2004, 104, 1094-1099. (Pubitemid 39038030)
58. Cwynarski, K.; Laylor, R.; Macchiarulo, E.; Goldman, J.; Lombardi, G.; Melo, J. V.; Dazzi, F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 2004, 18, 1332-1339. (Pubitemid 39136740)
59. Seggewiss, R.; Lore, K.; Greiner, E.; Magnusson, M. K.; Price, D. A.; Douek, D. C.; Dunbar, C. E.; Wiestner, A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood, 2005, 105, 2473-2479. (Pubitemid 40387048)
60. Sinai, P.; Berg, R. E.; Haynie, J. M.; Egorin, M. J.; Ilaria Jr., R. L.; Forman, J. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J. Immunol., 2007, 178, 2028-2037. (Pubitemid 46233399)
61. Mumprecht, S.; Matter, M.; Pavelic, V.; Ochsenbein, A. F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood, 2006, 108, 3406-3413.
62. Chen, J.; Schmitt, A.; Chen, B.; Rojewski, M.; Ringhoffer, M.; von Harsdorf, S.; Greiner, J.; Guillaume, P.; Dohner, H.; Bunjes, D.; Schmitt, M. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol. Immunother., 2007, 56, 849-861. (Pubitemid 46723580)
63. Leder, C.; Ortler, S.; Seggewiss, R.; Einsele, H.; Wiendl, H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp. Hematol., 2007, 35, 1266-1271. (Pubitemid 47088775)
64. Chen, J.; Schmitt, A.; Giannopoulos, K.; Chen, B.; Rojewski, M.; Dohner, H.; Bunjes, D.; Schmitt, M. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int. J. Oncol., 2007, 31, 1133-1139.
65. Larmonier, N.; Janikashvili, N.; LaCasse, C. J.; Larmonier, C. B.; Cantrell, J.; Situ, E.; Lundeen, T.; Bonnotte, B.; Katsanis, E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J. Immunol., 2008, 181, 6955-6963.
66. Placke, T.; Kopp, H. G.; Salih, H. R. Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin. Dev. Immunol., 2010, 2010, 239083.
67. Aswald, J. M.; Lipton, H. J.; Aswald, S.; Messner, H. A. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol. Ther., 2002, 7, 143-149. (Pubitemid 37531602)
68. Gao, H.; Lee, B. N.; Talpaz, M.; Donato, N. J.; Cortes, J. E.; Kantarjian, H. M.; Reuben, J. M. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia, 2005, 19, 1905-1911. (Pubitemid 41553998)
69. Bachy, E.; Bernaud, J.; Roy, P.; Rigal, D.; Nicolini, F. E. Quantitative and functional analyses of CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br. J. Haematol., 2011, 153, 139-143.
70. Blake, S.; Hughes, T. P.; Mayrhofer, G.; Lyons, A. B. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol., 2008, 127, 330-339.
71. Schade, A. E.; Schieven, G. L.; Townsend, R.; Jankowska, A. M.; Susulic, V.; Zhang, R.; Szpurka, H.; Maciejewski, J. P. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood, 2008,. 111, 1366-1377. (Pubitemid 351213423)
72. Weichsel, R.; Dix, C.; Wooldridge, L.; Clement, M.; Fenton-May, A.; Sewell, A. K.; Zezula, J.; Greiner, E.; Gostick, E.; Price, D. A.; Einsele, H.; Seggewiss, R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res., 2008, 14, 2484-2491. (Pubitemid 351551084)
73. Fraser, C. K.; Blake, S. J.; Diener, K. R.; Lyons, A. B.; Brown, M. P.; Hughes, T. P.; Hayball, J. D. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol., 2009, 37, 256-265.
74. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Greiner, J.; Gotz, M.; Guillaume, P.; Dohner, H.; Bunjes, D.; Schmitt, M. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp. Hematol., 2008, 36:1297-1308.
75. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Gotz, M.; Dohner, H.; Bunjes, D.; Schmitt, M. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. B r. J. Haematol., 2009, 144, 195-205.
76. Lee, K. C.; Ouwehand, I.; Giannini, A. L.; Thomas, N. S.; Dibb, N. J.; Bijlmakers, M. J. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia, 2010, 24, 896-900.
77. Mustjoki, S.; Ekblom, M.; Arstila, T. P.; Dybedal, I.; Epling-Burnette, P. K.; Guilhot, F.; Hjorth-Hansen, H.; Hoglund, M.; Kovanen, P.; Laurinolli, T.; Liesveld, J.; Paquette, R.; Pinilla-Ibarz, J.; Rauhala, A.; Shah, N.; Simonsson, B.; Sinisalo, M.; Steegmann, J. L.; Stenke, L.; Porkka, K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia, 2009, 23, 1398-1405.
78. Kreutzman, A.; Juvonen, V.; Kairisto, V.; Ekblom, M.; Stenke, L.; Seggewiss, R.; Porkka, K.; Mustjoki, S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood, 2010, 116, 772-782.
79. Kreutzman, A.; Ladell, K.; Koechel, C.; Gostick, E.; Ekblom, M.; Stenke, L.; Melo, T.; Einsele, H.; Porkka, K.; Price, D. A.; Mustjoki, S.; Seggewiss, R. Expansion of highly differentiated CD8 (+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia., 2011, [epub ahead of print].
80. Chen, J.; Schmitt, A.; Chen, B.; Rojewski, M.; Rubeler, V.; Fei, F.; Yu, Y.; Yu, X.; Ringhoffer, M.; von Harsdorf, S.; Greiner, J.; Gotzz, M.; Guillaume, P.; Dohner, H.; Bunjes, D.; Schmitt, M. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J. Cell Mol. Med., 2008, 12, 2107-2118.
81. Blake, S. J.; Lyons, A. B.; Hughes, T. P. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J. Cell Mol. Med., 2009, 13, 599-601.
82. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Greiner, J.; Gotz, M.; Bunjes, D.; Schmitt, M. Effects of nilotinib on regulatory T cells: the dose matters. Mol. Cancer, 2010, 9, 22.
83. Peng, B.; Hayes, M.; Resta, D.; Racine-Poon, A.; Druker, B. J.; Talpaz, M.; Sawyers, C. L.; Rosamilia, M.; Ford, J.; Lloyd, P.; Capdeville, R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol., 2004, 22, 935-942. (Pubitemid 41103606)
84. Lanier, L. L. NK cell recognition. Annu. Rev. Immunol., 2005, 23, 225-274. (Pubitemid 40563170)
85. Caligiuri, M. A. Human natural killer cells. Blood, 2008, 112, 461-469.
86. Vivier, E.; Raulet, D. H.; Moretta, A.; Caligiuri, M. A.; Zitvogel, L.; Lanier, L. L.; Yokoyama, W. M.; Ugolini, S. Innate or adaptive immunity? The example of natural killer cells. Science, 2011, 331:44-49.
87. Ruggeri, L.; Capanni, M.; Urbani, E.; Perruccio, K.; Shlomchik, W. D.; Tosti, A.; Posati, S.; Rogaia, D.; Frassoni, F.; Aversa, F.; Martelli, M. F.; Velardi, A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, 295, 2097-2100. (Pubitemid 34229476)
88. Giebel, S.; Locatelli, F.; Lamparelli, T.; Velardi, A.; Davies, S.; Frumento, G.; Maccario, R.; Bonetti, F.; Wojnar, J.; Martinetti, M.; Frassoni, F.; Giorgiani, G.; Bacigalupo, A.; Holowiecki, J. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 2003, 102, 814-819. (Pubitemid 36917769)
89. Elkins, W. L.; Pickard, A.; Pierson, G. R. Deficient expression of class-I HLA in some cases of acute leukemia. Cancer Immunol. Immunother., 1984, 18, 91-100. (Pubitemid 15213361)
90. Demanet, C.; Mulder, A.; Deneys, V.; Worsham, M. J.; Maes, P.; Claas, F. H.; Ferrone, S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood, 2004, 103, 3122-3130. (Pubitemid 38451690)
91. Ljunggren, H. G.; Malmberg, K. J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol., 2007, 7, 329-339.
92. Salih, J.; Hilpert, J.; Placke, T.; Grunebach, F.; Steinle, A.; Salih, H. R.; Krusch, M. The BCR/ABL-inhibitors imatinib, nilotinib, and dasatinib differentially affect NK cell reactivity. Int. J. Cancer., 2010, 127, 2119-2128.
93. Blake, S. J.; Bruce, L. A.; Fraser, C. K.; Hayball, J. D.; Hughes, T. P. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood, 2008, 111, 4415-4416.
94. Djeu, J. Y.; Jiang, K.; Wei, S. A view to a kill: signals triggering cytotoxicity. Clin. Cancer Res., 2002, 8, 636-640. (Pubitemid 34745987)
95. Kim, D. H.; Kamel-Reid, S.; Chang, H.; Sutherland, R.; Jung, C. W.; Kim, H. J.; Lee, J. J.; Lipton, J. H. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica, 2009, 94, 135-139.
96. Baron, F.; Turhan, A. G.; Giron-Michel, J.; Azzarone, B.; Bentires-Alj, M.; Bours, V.; Bourhis, J. H.; Chouaib, S.; Caignard, A. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood, 2002, 99, 2107-2113. (Pubitemid 34525495)
97. Cebo, C.; Voutsadakis, I. A.; Da Rocha, S.; Bourhis, J. H.; Jalil, A.; Azzarone, B.; Turhan, A. G.; Chelbi-Alix, M.; Chouaib, S.; Caignard, A. Altered IFN-gamma signaling and preserved susceptibility to activated natural killer cellmediated lysis of BCR/ABL targets. Cancer Res., 2005, 65, 2914-2920. (Pubitemid 40490096)
98. Cebo, C.; Da Rocha, S.; Wittnebel, S.; Turhan, A. G.; Abdelali, J.; Caillat-Zucman, S.; Bourhis, J. H.; Chouaib, S.; Caignard, A. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J. Immunol., 2006, 176, 864-872. (Pubitemid 43099683)
99. Boissel, N.; Rea, D.; Tieng, V.; Dulphy, N.; Brun, M.; Cayuela, J. M.; Rousselot, P.; Tamouza, R.; Le Bouteiller, P.; Mahon, F. X.; Steinle, A.; Charron, D.; Dombret, H.; Toubert, A. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol., 2006, 176, 5108-5116.
100. Ogasawara, K.; Hamerman, J. A.; Hsin, H.; Chikuma, S.; Bour-Jordan, H.; Chen, T.; Pertel, T.; Carnaud, C.; Bluestone, J. A.; Lanier, L. L. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity., 2003, 18, 41-51. (Pubitemid 36120686)
101. Walzer, T.; Dalod, M.; Robbins, S. H.; Zitvogel, L.; Vivier, E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood, 2005, 106, 2252-2258. (Pubitemid 41510793)
102. Terme, M.; Borg, C.; Guilhot, F.; Masurier, C.; Flament, C.; Wagner, E. F.; Caillat-Zucman, S.; Bernheim, A.; Turhan, A. G.; Caignard, A.; Zitvogel, L. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res., 2005, 65, 6409-6417. (Pubitemid 40994429)
103. Borg, C.; Terme, M.; Taieb, J.; Menard, C.; Flament, C.; Robert, C.; Maruyama, K.; Wakasugi, H.; Angevin, E.; Thielemans, K.; Le Cesne, A.; Chung-Scott, V.; Lazar, V.; Tchou, I.; Crepineau, F.; Lemoine, F.; Bernard, J.; Fletcher, J. A.; Turhan, A.; Blay, J. Y.; Spatz, A.; Emile, J. F.; Heinrich, M. C.; Mecheri, S.; Tursz, T.; Zitvogel, L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest, 2004, 114, 379-388. (Pubitemid 39071610)
104. Greiner, J.; Schmitt, M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur. J. Haematol., 2008, 80, 461-468. (Pubitemid 351677457)
105. Hofmann, S.; Babiak, A.; Greiner, J. Immunotherapy for myeloproliferative neoplasms (MPN). Curr. Cancer Drug Targets., 2011, 11, 72-84.
106. Simonsson, B.; Gedde-Dahl, T.; Markevarn, B.; Remes, K.; Stentoft, J.; Almqvist, A.; Bjoreman, M.; Flogegard, M.; Koskenveesa, P.; Lindblom, A.; Malm, C.; Mustjoki, S.; Myhr-Eriksson, K.; Ohm, L.; Rasanen, A.; Sinisalo, M.; Sjalander, A.; Stromberg, U.; Weiss, B. O.; Ehrencrona, H.; Gruber, F.; Kairisto, V.; Olsson, K.; Sandin, F.; Nagler, A.; Lanng, N. J.; Hjorth-Hansen, H.; Porkka, K. Combination of pegylated interferon-{alpha}2b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia. Blood., 2011, [epub ahead of print].
107. Burchert, A.; Muller, M. C.; Kostrewa, P.; Erben, P.; Bostel, T.; Liebler, S.; Hehlmann, R.; Neubauer, A.; Hochhaus, A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol., 2010, 28, 1429-1435.